Omega-3 fatty acids have been studied for their effects on Glutathione levels
Phase 2 Clinical Trial Data The landmark Phase 2 trial of retatrutide in obesity was a 48-week, randomized, double-blind, placebo-controlled study published in The New England Journal of Medicine in 2023
Glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide, play a crucial role in glucose metabolism by enhancing the glucose-dependent secretion of insulin from pancreatic beta cells and inhibiting glucagon release from alpha cells, thus lowering blood glucose levels postprandially (Holst, 2007)
Stay tuned for sub-analyses from that trial for more info
W.SelbyN
Last quarter, the company submitted its drug orforglipron, a new GLP-1 agonist, for obesity treatment in the United States and more than three dozen additional countries, with an expected domestic launch by mid-2026